FI3823990T3 - Cd19:ään sitoutuvia raskasketjun vasta-aineita - Google Patents
Cd19:ään sitoutuvia raskasketjun vasta-aineitaInfo
- Publication number
- FI3823990T3 FI3823990T3 FIEP19749123.6T FI19749123T FI3823990T3 FI 3823990 T3 FI3823990 T3 FI 3823990T3 FI 19749123 T FI19749123 T FI 19749123T FI 3823990 T3 FI3823990 T3 FI 3823990T3
- Authority
- FI
- Finland
- Prior art keywords
- heavy chain
- antibody
- multispecific
- seq
- multispecific antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701281P | 2018-07-20 | 2018-07-20 | |
| PCT/US2019/042633 WO2020018922A1 (en) | 2018-07-20 | 2019-07-19 | Heavy chain antibodies binding to cd19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3823990T3 true FI3823990T3 (fi) | 2026-03-16 |
Family
ID=67515196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP19749123.6T FI3823990T3 (fi) | 2018-07-20 | 2019-07-19 | Cd19:ään sitoutuvia raskasketjun vasta-aineita |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12202898B2 (https=) |
| EP (2) | EP3823990B1 (https=) |
| JP (2) | JP7439046B2 (https=) |
| KR (2) | KR20260036383A (https=) |
| CN (2) | CN112351997B (https=) |
| AU (1) | AU2019305663B2 (https=) |
| BR (1) | BR112020024074A2 (https=) |
| CA (1) | CA3101069A1 (https=) |
| DK (1) | DK3823990T3 (https=) |
| FI (1) | FI3823990T3 (https=) |
| HR (1) | HRP20260372T1 (https=) |
| IL (2) | IL326259A (https=) |
| LT (1) | LT3823990T (https=) |
| MX (1) | MX2021000708A (https=) |
| PL (1) | PL3823990T3 (https=) |
| PT (1) | PT3823990T (https=) |
| SG (1) | SG11202011597RA (https=) |
| WO (1) | WO2020018922A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3029209A1 (en) | 2016-06-21 | 2017-12-28 | Teneobio, Inc. | Cd3 binding antibodies |
| IL264941B2 (en) | 2016-08-24 | 2025-12-01 | Teneobio Inc | Transgenic non-human animals producing modified heavy chain-only antibodies |
| FI4050034T3 (fi) | 2016-09-14 | 2024-06-10 | Teneoone Inc | Cd3:een sitoutuvia vasta-aineita |
| NZ754713A (en) | 2016-12-21 | 2025-11-28 | Teneobio Inc | Anti-bcma heavy chain-only antibodies |
| US11427642B2 (en) | 2017-06-20 | 2022-08-30 | Teneoone, Inc. | Anti-BCMA heavy chain-only antibodies |
| IL271194B2 (en) | 2017-06-20 | 2024-10-01 | Teneobio Inc | Anti-bcma heavy chain-only antibodies |
| WO2019126756A1 (en) | 2017-12-22 | 2019-06-27 | Teneobio, Inc. | Heavy chain antibodies binding to cd22 |
| PL3823990T3 (pl) | 2018-07-20 | 2026-04-20 | TeneoTwo, Inc. | Przeciwciała łańcucha ciężkiego wiążące się z cd19 |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| JP7776987B2 (ja) | 2019-04-05 | 2025-11-27 | テネオバイオ， インコーポレイテッド | Ｐｓｍａに結合する重鎖抗体 |
| CN114206927B (zh) | 2019-06-14 | 2025-03-21 | 特尼奥生物股份有限公司 | 与cd22和cd3结合的多特异性重链抗体 |
| JP2023518049A (ja) | 2020-03-16 | 2023-04-27 | ユニバーシティ オブ サザン カリフォルニア | 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体 |
| TWI838621B (zh) | 2020-04-29 | 2024-04-11 | 美商泰尼歐萬公司 | 具有經修飾重鏈恆定區之多特異性重鏈抗體 |
| AU2021263448B2 (en) | 2020-04-29 | 2026-02-05 | Teneobio, Inc. | Multispecific heavy chain antibodies with modified heavy chain constant regions |
| KR20230038706A (ko) * | 2020-07-16 | 2023-03-21 | 난징 레전드 바이오테크 씨오., 엘티디. | Cd19 결합 분자 및 이의 용도 |
| JP7846667B2 (ja) | 2020-07-16 | 2026-04-15 | レジェンド バイオテック アイルランド リミテッド | Ｃｄ２０結合分子及びその使用 |
| EP4214233A1 (en) | 2020-09-16 | 2023-07-26 | Amgen Inc. | Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer |
| PE20232050A1 (es) * | 2021-04-06 | 2023-12-27 | Teneobio Inc | Anticuerpos anti-cd19 y estructuras car-t |
| WO2024243093A2 (en) * | 2023-05-19 | 2024-11-28 | The Regents Of The University Of California | Multispecific antibodies targeting cd3 and cd22 |
| EP4566619A1 (en) | 2023-12-08 | 2025-06-11 | AvenCell Therapeutics Inc. | Targeting modules against cd19 and cd20 for use in a method for stimulating a reversed chimeric antigen receptor-mediated immune response in a mammal |
| WO2025222102A1 (en) * | 2024-04-19 | 2025-10-23 | TeneoTwo, Inc. | Therapeutic combinations of acalabrutinib and a multispecific antibody to treat b-cell malignancies |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US6066721A (en) | 1995-07-06 | 2000-05-23 | Stanford University | Method to produce novel polyketides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| WO2001024812A1 (en) | 1999-10-06 | 2001-04-12 | N.V. Nutricia | USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA |
| UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| US20030012783A1 (en) | 2001-02-20 | 2003-01-16 | Wayne Kindsvogel | Antibodies that bind both BCMA and TACI |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| WO2004042017A2 (en) | 2002-10-31 | 2004-05-21 | Genentech, Inc. | Methods and compositions for increasing antibody production |
| CA2513113A1 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| US20060008548A1 (en) | 2003-11-19 | 2006-01-12 | Invista North America S.A R.L. | Spinneret plate for producing a bulked continuous filament having a three-sided exterior cross-section and a convex six-sided central void |
| SI2311874T1 (sl) | 2004-07-22 | 2017-12-29 | Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics | Vezavne molekule |
| CN101218351A (zh) * | 2005-02-15 | 2008-07-09 | 杜克大学 | 抗cd19抗体及其在肿瘤学中的应用 |
| KR101335798B1 (ko) * | 2005-02-15 | 2013-12-02 | 듀크 유니버시티 | 항-ｃｄ19 항체 및 종양학에서 이의 용도 |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| DK2602323T3 (en) | 2007-06-01 | 2018-04-16 | Open Monoclonal Tech Inc | Compositions and Methods for Inhibiting Endogenous Immunoglobin Genes and Producing Transgenic Human Idiotypic Antibodies |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| KR101314369B1 (ko) * | 2008-07-17 | 2013-10-10 | 노파르티스 아게 | 치료학적 항체에 대한 조성물 및 사용 방법 |
| EP2406284B9 (en) | 2009-03-10 | 2017-03-01 | Biogen MA Inc. | Anti-bcma antibodies |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| JP6636803B2 (ja) | 2013-02-05 | 2020-01-29 | エンクマフ エスアーエールエル | Ｂｃｍａに対する抗体の選択のための方法 |
| EA201790719A1 (ru) | 2014-09-26 | 2017-07-31 | Макродженикс, Инк. | Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| US9914683B2 (en) | 2016-05-26 | 2018-03-13 | X Development Llc | Fuel synthesis from an aqueous solution |
| CA3029209A1 (en) | 2016-06-21 | 2017-12-28 | Teneobio, Inc. | Cd3 binding antibodies |
| IL264941B2 (en) * | 2016-08-24 | 2025-12-01 | Teneobio Inc | Transgenic non-human animals producing modified heavy chain-only antibodies |
| FI4050034T3 (fi) | 2016-09-14 | 2024-06-10 | Teneoone Inc | Cd3:een sitoutuvia vasta-aineita |
| NZ754713A (en) | 2016-12-21 | 2025-11-28 | Teneobio Inc | Anti-bcma heavy chain-only antibodies |
| IL271194B2 (en) | 2017-06-20 | 2024-10-01 | Teneobio Inc | Anti-bcma heavy chain-only antibodies |
| US11427642B2 (en) | 2017-06-20 | 2022-08-30 | Teneoone, Inc. | Anti-BCMA heavy chain-only antibodies |
| US20200138865A1 (en) | 2017-06-30 | 2020-05-07 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Anti-b-cell maturation antigen chimeric antigen receptors with human domains |
| RU2020124623A (ru) | 2017-12-27 | 2022-01-27 | Тенеобио, Инк. | Антитела, специфичные к гетеродимеру cd3-дельта/эпсилон |
| SG11202011589WA (en) | 2018-05-24 | 2020-12-30 | Ayala Pharmaceuticals Inc | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and immunotherapeutics and methods of use thereof |
| PL3823990T3 (pl) | 2018-07-20 | 2026-04-20 | TeneoTwo, Inc. | Przeciwciała łańcucha ciężkiego wiążące się z cd19 |
| CN114206927B (zh) | 2019-06-14 | 2025-03-21 | 特尼奥生物股份有限公司 | 与cd22和cd3结合的多特异性重链抗体 |
| AU2021263448B2 (en) | 2020-04-29 | 2026-02-05 | Teneobio, Inc. | Multispecific heavy chain antibodies with modified heavy chain constant regions |
-
2019
- 2019-07-19 PL PL19749123.6T patent/PL3823990T3/pl unknown
- 2019-07-19 CA CA3101069A patent/CA3101069A1/en active Pending
- 2019-07-19 EP EP19749123.6A patent/EP3823990B1/en active Active
- 2019-07-19 JP JP2021502833A patent/JP7439046B2/ja active Active
- 2019-07-19 IL IL326259A patent/IL326259A/en unknown
- 2019-07-19 MX MX2021000708A patent/MX2021000708A/es unknown
- 2019-07-19 CN CN201980035712.8A patent/CN112351997B/zh active Active
- 2019-07-19 US US17/260,213 patent/US12202898B2/en active Active
- 2019-07-19 AU AU2019305663A patent/AU2019305663B2/en active Active
- 2019-07-19 BR BR112020024074-5A patent/BR112020024074A2/pt unknown
- 2019-07-19 CN CN202310539593.8A patent/CN116769032A/zh active Pending
- 2019-07-19 SG SG11202011597RA patent/SG11202011597RA/en unknown
- 2019-07-19 WO PCT/US2019/042633 patent/WO2020018922A1/en not_active Ceased
- 2019-07-19 DK DK19749123.6T patent/DK3823990T3/da active
- 2019-07-19 PT PT197491236T patent/PT3823990T/pt unknown
- 2019-07-19 EP EP25219867.6A patent/EP4714502A2/en active Pending
- 2019-07-19 LT LTEPPCT/US2019/042633T patent/LT3823990T/lt unknown
- 2019-07-19 KR KR1020267005215A patent/KR20260036383A/ko active Pending
- 2019-07-19 HR HRP20260372TT patent/HRP20260372T1/hr unknown
- 2019-07-19 FI FIEP19749123.6T patent/FI3823990T3/fi active
- 2019-07-19 KR KR1020207034987A patent/KR102930803B1/ko active Active
-
2020
- 2020-11-26 IL IL279010A patent/IL279010B1/en unknown
-
2024
- 2024-02-14 JP JP2024020312A patent/JP7737488B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021000708A (es) | 2021-03-25 |
| JP7439046B2 (ja) | 2024-02-27 |
| WO2020018922A1 (en) | 2020-01-23 |
| CN112351997A (zh) | 2021-02-09 |
| LT3823990T (lt) | 2026-04-10 |
| CN116769032A (zh) | 2023-09-19 |
| US12202898B2 (en) | 2025-01-21 |
| US20210332133A1 (en) | 2021-10-28 |
| EP4714502A2 (en) | 2026-03-25 |
| JP2024073430A (ja) | 2024-05-29 |
| EP3823990A1 (en) | 2021-05-26 |
| CA3101069A1 (en) | 2020-01-23 |
| KR20260036383A (ko) | 2026-03-16 |
| PL3823990T3 (pl) | 2026-04-20 |
| HRP20260372T1 (hr) | 2026-04-24 |
| AU2019305663B2 (en) | 2026-04-02 |
| SG11202011597RA (en) | 2020-12-30 |
| CN112351997B (zh) | 2023-05-26 |
| EP3823990B1 (en) | 2025-12-17 |
| BR112020024074A2 (pt) | 2021-02-17 |
| AU2019305663A1 (en) | 2021-03-11 |
| IL279010A (en) | 2021-01-31 |
| KR20210032311A (ko) | 2021-03-24 |
| IL326259A (en) | 2026-03-01 |
| JP2021530236A (ja) | 2021-11-11 |
| DK3823990T3 (da) | 2026-03-16 |
| KR102930803B1 (ko) | 2026-02-26 |
| PT3823990T (pt) | 2026-03-20 |
| IL279010B1 (en) | 2026-03-01 |
| JP7737488B2 (ja) | 2025-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3823990T3 (fi) | Cd19:ään sitoutuvia raskasketjun vasta-aineita | |
| JP2021527431A5 (https=) | ||
| PH12020551173A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| FI3322727T3 (fi) | Humanisoituja tai kimeerisiä CD3-vasta-aineita | |
| PH12019502785A1 (en) | Anti trbc1 antigen binding domains | |
| JP2021530236A5 (https=) | ||
| FI3826667T3 (fi) | Claudin6 vasta-aineita ja menetelmiä syövän hoitamiseksi | |
| FI3332006T3 (fi) | Uusia anti-PD-L1-vasta-aineita | |
| JP2017535257A5 (https=) | ||
| MY200988A (en) | CD3 Binding Antibodies | |
| IL265541B1 (en) | Bispecific antibodies and compositions comprising thereof for treating cancer | |
| RU2010100638A (ru) | Композиции и способы лечения, направленные против cd20 | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| RU2016124540A (ru) | Композиции, содержащие анти-сеасам 1 и анти-pd антитела для терапии рака | |
| JP2018532383A5 (https=) | ||
| RU2016129517A (ru) | Биспецифические антитела к her2 и способы применения | |
| JP2016533763A5 (ja) | ヒトｐｄ−１に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物 | |
| JP2018528776A5 (https=) | ||
| RU2014122990A (ru) | Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas | |
| PE20231080A1 (es) | Anticuerpos que se unen a cd3 y cd19 | |
| IL280487B2 (en) | Anti-mica/b antibodies that block mica/b shedding and methods of use | |
| RU2014153440A (ru) | Антитела против cd26 и их применение | |
| WO2020257789A3 (en) | Anti-tim-3 antibodies | |
| IL250289B2 (en) | Antibodies against angiopoietin-like 4 and methods of use | |
| JP2016529213A5 (https=) |